Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (March 2022)
34 slides from Prescient Therapeutics's investor presentation, Mar 1, 2022
Slide 1: Prescient Therapeutics – Investor Briefing
Prescient Therapeutics – Investor Briefing For personal use only MELBOURNE Australia, 1 March 2022 – Prescient Therapeutics (ASX: PTX), a clinical stage oncology company developing personalised therapies to treat cancer, is pleased to announce that they will be holding an investor briefing on Thursd
Slide 2: About Prescient Therapeutics Limited (Prescient)
About Prescient Therapeutics Limited (Prescient) Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies. For personal use only Cell Therapies OmniCAR: is a universal immune receptor platform enablin
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward- For personal use only looking statements are not histori
Slide 4: In Front of the Biggest Wave in Oncology
For personal use only IN FRONT OF THE BIGGEST WAVE IN ONCOLOGY March 2022 1
Slide 5: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on
Slide 6: Investment Highlights
Investment Highlights For personal use only World class pedigree. Game-changing cell therapy We license from the best; and platform work with the best 3 highly differentiated next-gen Many shots on goal for CAR-T programs: substantial value creation 1. AML 2. Her2+ solid tumors 3. GBM PTX-100: FIC R
Slide 7: Corporate Snapshot
Corporate Snapshot For personal use only ASX Ticker PTX Total Issued Capital 648 M shares Listed Options 95.4 M Unlisted Options 12.1 M Share Price1 A$0.16 (US$0.12) Market A$103 M Capitalisation1 (US$74 M) Market Cap fully A$119 M diluted1 (US$85 M) Cash Position2 A$14.7M (US$11M) Top 20 Own 17% 1
Slide 8: Innovative Pipeline in Personalised Medicine
Innovative Pipeline in Personalised Medicine For personal use only Program Discovery Screening Preclinical Phase I Phase IB Phase II OmniCAR CD33 & CLL-1 AML OmniCAR HER2 Breast, Ovarian & Gastric cancers OmniCAR GBM Her2 & EGFRviii Targeted Therapies Cell Therapy Undisclosed Enhancements PTX - 100
Slide 9: PTX-100: First in Class Ras Pathway Inhibitor
For personal use only PTX-100 FIRST IN CLASS RAS PATHWAY INHIBITOR 6
Slide 10: PTX-100 Phase 1b Summary
PTX-100 PHASE 1B SUMMARY For personal use only Excellent safety profile • No serious safety issues related to PTX-100 Early clinical activity Professor H. Miles Prince, AM • Expected PFS of <4 months on SoC Principal Investigator • PRs in 2 patients with aggressive refractory TCL 1. 12 months 2. 17
Slide 11: Progressing to Expansion Cohort
PROGRESSING TO EXPANSION COHORT For personal use only Case Study • 8 – 12 patients with r/r T cell lymphoma • pralatrexate (Folotyn®) (esp PTCL) • Approved for PTCL • Potential bridge to registration study • 5,600 cases/year in US • Focussing on sweet spot in an area of • US$450,540 per patient, per
Slide 12: PTX-200: Novel Akt Inhibition
For personal use only PTX-200 NOVEL AKT INHIBITION 9
Slide 13: Phase 1b Trial Underway: Acute Myeloid Leukemia
PHASE 1B TRIAL UNDERWAY: ACUTE MYELOID LEUKEMIA For personal use only • Building upon encouraging Phase 1 results with PTX-200 (monotherapy) • PI Professor Jeff Lancet at Moffitt, Key Opinion Leader in AML • 18 patients with cytarabine held constant at 200-400 mg/m2 as continuous infusion Jeffrey E
Slide 14: Universal, Next Generation CAR-T
For personal use only Universal, Next Generation CAR-T 11
Slide 15: How does the CAR-T process work?
How does the CAR-T process work? For personal use only 1. 2. Blood is collected from the T- Cells are separated and patient removed 3. T-Cells are genetically altered to have special cancer-recognising receptors 5. called Chimeric Antigen Receptor Patient first receives (CAR) Chemotherapy, and then
Slide 16: February 2022
For personal use only 2 February 2022 13
Slide 17: Penn is a pioneer and world leader in CAR-T
Penn is a pioneer and world leader in CAR-T For personal use only Novartis licensed CAR-T technology from Penn in 2012 Kymriah® became the first CAR-T therapy approved by the FDA Used for certain blood cancers Cost of treatment in excess of $500,000 per treatment GlobalData forecasts Kymriah® sales
Slide 18: Key Challenges confronting the field of CAR-T
Key Challenges confronting the field of CAR-T For personal use only Targets Time and Cost Finding targets that work; of delivering treatment Antigen heterogeneity - esp. in solid tumours Safety Exhaustion CAR-T can have Persistent stimulation of CAR- serious safety Immune cells leads to exhaustion c
Slide 19: OmniCAR: flexible, modular CAR platform
OmniCAR: flexible, modular CAR platform For personal use only Targeting ligand Using any SpyTag targeting Covalent bond ligand… Spy Catcher Associate Professor Professor Daniel J. Powell, Jr Andrew Tsourkas Signalling domain …with any UNARMED ARMED immune CAR-T cell CAR-T cell cell 16
Slide 20: OmniCAR can do what conventional CAR-T cannot
OmniCAR can do what conventional CAR-T cannot For personal use only Conventional CAR-T Can be given any map; Armed with any weapon Multiple deployments Including several at once • Soldier with only one map • Single weapon Full communication • Only trained to hit one target and control at all times,
Slide 21: OmniCAR Platform Business Model
OmniCAR Platform Business Model For personal use only Next generation Collaborate & license products in-house to third parties OmniCAR CD33/CLL1 Potential partner for AML based on Targets Potential partner OmniCAR Her2 based on for Solid Tumours Specific Constructs Potential partner OmniCAR Her2/EGF
Slide 22: Control: Dose-dependent CAR-T activity
Control: Dose-dependent CAR-T activity For personal use only • Ovarian cancer model, using anti-HER2 OmniCAR • Loading more binder results in proportionate killing of cancer… • …and proportionate survival • Lasting effects even when cease dosing of binder Powell, DJ et al, JACS; 2020 = dosing window
Slide 23: OmniCAR cells can be Re-Armed
OmniCAR cells can be Re-Armed T cell activation Transduction Armed Cytotoxicity assay For personal use only Day 0 Day 3 Day 7 Days 8–10 Re-armed Cytotoxicity assay Wash; Rest 2:1 OmniCARDay Her2 12 normalised post-REP Days 13–14 2:1 OmniCAR Her2Anormalised pre-REP B 150 150 Tumour alone Washed OmniC
Slide 24: OmniCAR cells can be Redirected
OmniCAR cells can be Redirected Coculture of U251 GBM Cells For personal use only expressing HER2 or EGFRviii • Rapid cytotoxicity to EGFRviii • Rapid switching and cytotoxicity against HER2+ tumours upon administration of new binder • OmniCAR cells can be re-directed to different antigens upon admi
Slide 25: OmniCAR manufacturing advantages
OmniCAR manufacturing advantages For personal use only Conventional CAR-T Run 1 Individual production runs for each Single production run for CAR-T product OmniCAR Auto T-cell • Expensive ($’000k / run) Run 2 • Time consuming (22 days/run) Subsequent administration of binders • Cannot redirect to ne
Slide 26: What's the Endgame?
For personal use only What’s the Endgame? 23
Slide 27: The Apple Ecosystem
The Apple Ecosystem For personal use only 24
Slide 28: Personalized Plug & Play Cell Therapy Ecosystem
Personalized “Plug & Play” Cell Therapy Ecosystem Step 3: For personal use only Step 4: OmniCAR- induced Pair binders with tumor killing with OmniCAR cells post-infusion control (T cells; NK; auto/allo) Step 2: Match patient’s antigens to corresponding binders Step 1: Patient sample to determine ind
Slide 29: Summary
For personal use only Summary 26
Slide 30: Key building blocks to PTX Future Value
Key building blocks to PTX Future Value 1 2 3 For personal use only OmniCAR Cell Therapy Targeted Enhancements therapies • Next generation • Enhancing current universal CAR platform generation CAR-T • PTX-100 • AML • Also applicable to next • PTX-200 gen • Her2+ solid tumours • Collaboration with Pe
Slide 31: Multiple catalysts in 2022
Multiple catalysts in 2022 For personal use only • Ongoing business development • PTX-100 expansion cohort activities full recruitment (~Q4 2022) • Continuing to build awareness among investors, clinicians and corporates • Completion of enrolment in PTX-100 expansion cohort (Q2/3 2022) • Announce fu
Slide 32: Compelling investment case!
Compelling investment case! For personal use only World class pedigree. Game-changing cell therapy We license from the best; and platform work with the best 3 highly differentiated next-gen Many shots on goal for CAR-T programs: substantial value creation 1. AML 2. Her2+ solid tumors 3. GBM PTX-100:
Slide 33: Top-down analysis is sensible for investors
Top-down analysis is sensible for investors For personal use only 1 Biggest Market in Oncology Healthcare? US$145B* 2 Fastest growing area Cell Therapies (CAR-T) in oncology? Scalable 3 Forefront of Controllable Cell Therapy? Any target Any immune cell *Statista.com; sales in 2019
Slide 34: Thank you!
For personal use only Thank you! ASX code: PTX www.ptxtherapeutics.com
Prescient Therapeutics — Investor Presentation (March 2022) on 6ix